Palisade Bio Reports Q1 Results, Highlights Positive PALI-2108 Data & Extends Cash Runway

summarizeSummary

Palisade Bio reported increased Q1 net loss and operating expenses but highlighted a strong cash position of $132.6 million, extending its runway through key Phase 2 clinical readouts for PALI-2108, which continues to show positive data and is advancing to Phase 2 trials.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $9.6 million for Q1 2026, a significant increase from $2.2 million in Q1 2025, driven by higher research and development ($6.4M vs $1.0M) and general and administrative expenses ($4.4M vs $1.4M).

• Strong Cash Position and Runway

  Ended Q1 2026 with $132.6 million in cash and cash equivalents, expected to fund operations through major clinical development milestones, including Phase 2 readouts for PALI-2108 in late 2027 and early 2028.

• Positive PALI-2108 Clinical Data

  Highlighted continued positive Phase 1a/b data for PALI-2108, demonstrating a favorable safety profile, target engagement, and early signals of clinical activity in both ulcerative colitis and fibrostenotic Crohn's disease.

• Advancing to Phase 2 Trials

  Anticipates IND submissions for Phase 2 UC and CD trials in 2Q 2026 and 2H 2026, respectively, with trial initiations targeted for Q3 2026 (UC) and Q1 2027 (CD).

auto_awesomeAnalysis

This filing provides the detailed Q1 2026 financial results and critical updates on the company's lead clinical program, PALI-2108. While the company reported a significantly increased net loss and operating expenses, it also confirmed a strong cash position of $132.6 million, which is projected to fund operations through key Phase 2 clinical readouts in late 2027 and early 2028. For a clinical-stage biotech, securing a long cash runway and advancing its pipeline are paramount, making these updates important for assessing the company's operational viability and future prospects.